ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Cabergoline: Drug information

Cabergoline: Drug information
(For additional information see "Cabergoline: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • ACT Cabergoline [DSC];
  • APO-Cabergoline;
  • Dostinex
Pharmacologic Category
  • Ergot Derivative;
  • Hyperprolactinemia Agent, Dopamine (D2) Agonist
Dosing: Adult

Note: Safety: Use the lowest effective dose; periodic monitoring for cardiac valve abnormalities (eg, echocardiogram) is suggested in patients receiving doses >2 mg/week (Ref).

Acromegaly

Acromegaly (off-label use): Oral: Initial: 0.25 to 0.5 mg two times per week; titrate as needed every 4 to 6 weeks based on insulin-like growth factor 1 (IGF-1) and growth hormone levels; usual dosage range: 0.5 to 3.5 mg/week (mean dose: ~2 mg/week) (Ref). Note: Doses up to 7 mg/week have been studied in a small number of patients; doses >2 mg/week may not be more efficacious in suppressing IGF-1 levels (Ref).

Cushing disease

Cushing disease (off-label use): Oral: Initial: 0.5 mg administered once or twice weekly; may increase by 0.5 to 1 mg/week every 1 to 2 months until urinary free cortisol levels normalize; usual dosage range: 1 to 7 mg/week (median dose: ~2 to 3.5 mg/week) (Ref).

Hyperprolactinemic disorders

Hyperprolactinemic disorders:

Oral: Initial: 0.25 to 0.5 mg/week administered in 1 or 2 divided weekly doses (Ref).

Dosage adjustment: May increase dose by 0.25 to 0.5 mg/week no sooner than every 4 weeks if needed based on serum prolactin levels (Di Sarno 2001; manufacturer's labeling); usual dosage range: 0.25 to 3 mg/week administered in 1 or 2 divided weekly doses (Ref). If higher doses are used, may administer in as many as 3 to 4 divided weekly doses (Ref).

Duration of therapy: Although the US labeling states that therapy may be discontinued after 6 months, treatment for ≥2 years has been recommended to reduce the risk of recurrence. Ensure that prolactin levels are normal and there is no visible tumor on MRI (in patients with prolactinoma) prior to tapering and discontinuing; maintenance of normal prolactin levels after tapering dosage to ≤0.5 mg/week may predict a lower risk of recurrence following discontinuation (Ref).

Lactation inhibition

Lactation inhibition (off-label use): Oral: 1 mg as a single dose within 48 hours postpartum (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, cabergoline pharmacokinetics are not altered in patients with moderate to severe renal impairment.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor carefully in patients with severe hepatic impairment (Child-Pugh class C) (extensive hepatic metabolism).

Dosing: Adjustment for Toxicity: Adult

Cardiac valvulopathy: Discontinue if an echocardiogram reveals new valvular regurgitation, valvular restriction, or valve leaflet thickening.

Dosing: Older Adult

Refer to adult dosing. Start at the low end of the dosage range.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%:

Gastrointestinal: Nausea (27% to 29%)

Nervous system: Dizziness (15% to 17%), headache (26%)

1% to 10%:

Cardiovascular: Dependent edema (1%), hypotension (≤1%), orthostatic hypotension (4%), palpitations (≤1%), peripheral edema (1%), syncope (≤1%)

Dermatologic: Acne vulgaris (≤1%), pruritus (≤1%)

Endocrine & metabolic: Hot flash (3%)

Gastrointestinal: Abdominal pain (5%), anorexia (≤1%), constipation (7% to 10%), diarrhea (≤2%), dyspepsia (2% to 5%), flatulence (≤2%), toothache (1%), vomiting (2% to 4%), xerostomia (≤2%)

Genitourinary: Dysmenorrhea (≤1%), mastalgia (1% to 2%)

Nervous system: Anxiety (≤1%), asthenia (6%), depression (3%), drowsiness (≤2%), fatigue (5% to 7%), insomnia (≤1%), lack of concentration (1%), malaise (≤1%), nervousness (≤2%), pain (2%), paresthesia (≤2%), vertigo (1% to 4%)

Neuromuscular & skeletal: Arthralgia (1%)

Ophthalmic: Periorbital edema (1%), visual disturbance (≤1%)

Respiratory: Flu-like symptoms (≤1%), rhinitis (1%), throat irritation (1%)

<1%:

Endocrine & metabolic: Increased libido (including hypersexuality), weight gain, weight loss

Hypersensitivity: Facial edema

Respiratory: Epistaxis, nasal congestion

Postmarketing:

Cardiovascular: Acquired valvular heart disease (Cawood 2009), constrictive pericarditis (Townsend 2004), coronary artery dissection (Mehta 2012)

Dermatologic: Alopecia (Miwa 2003)

Hematologic & oncologic: Autoimmune hemolytic anemia (Gürbüz 2014)

Nervous system: Aggressive behavior, impulse control disorder (Bulwer 2017), pathological gambling (Falhammar 2009), psychosis (Gupta 2018)

Respiratory: Interstitial pneumonitis (Frank 1999), pleural effusion (Belmonte 2009)

Miscellaneous: Fibrosis (extracardiac; including pericardial fibrosis, pleuropulmonary fibrosis, pulmonary fibrosis [Townsend 2004], retroperitoneal fibrosis)

Contraindications

Known hypersensitivity to cabergoline, ergot derivatives, or any component of the formulation; uncontrolled hypertension; history of cardiac valvular disorders (indicated by valvulopathy of any valve, thickening of valve leaflet, valve restriction, or mixed valve restriction stenosis); history of pulmonary, pericardial, or retroperitoneal fibrotic disorders.

Warnings/Precautions

Concerns related to adverse effects:

• Cardiac valvulopathy: Cardiac valvulopathy has been reported with use. Risk is increased with use of high doses (eg, >2 mg/day). Although some conflicting data exist, a majority of observational evidence suggests the risk of valvulopathy in patients receiving typical low dose regimens (eg, ≤2 mg/week) is minimal or absent (Budayr 2020; ES [Katznelson 2014]; ES [Melmed 2011]; Stiles 2021).

• Cardiovascular effects: Initial doses >1 mg may cause orthostatic hypotension; may be symptomatic. Use with caution in patients with cardiovascular disease; hypertension, stroke, and seizure have been reported with other dopamine agonists. Concurrent use with antihypertensives may increase risk.

• CNS depression: May cause somnolence, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).

• Pleural/retroperitoneal fibrosis: Cases of pleural, pericardial, and retroperitoneal fibrosis have been reported. Do not use in patients with a history of cardiac or extracardiac fibrotic disorders. Following diagnosis of fibrosis, discontinuation of cabergoline may result in improvement of condition.

• Psychiatric disorders: Aggression, psychotic behavior, and impulse control disorders such as pathological gambling, increased libido, hypersexuality, compulsive spending or buying, and binge-eating have been reported with use; generally reversible with dose reduction or discontinuation of treatment.

Disease-related concerns:

• Hepatic impairment: Use with caution and carefully monitor patients with hepatic impairment; extensive hepatic metabolism.

• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease (PUD) or GI bleeding.

• Raynaud syndrome: Use with caution in patients with Raynaud syndrome.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 0.5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Cabergoline Oral)

0.5 mg (per each): $36.66

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Dostinex: 0.5 mg

Generic: 0.5 mg

Administration: Adult

Oral: Administer with meals (may increase tolerability).

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 3]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).

Use: Labeled Indications

Hyperprolactinemic disorders: Treatment of hyperprolactinemic disorders, either idiopathic or caused by pituitary adenomas.

Use: Off-Label: Adult

Acromegaly; Cushing disease; Lactation inhibition

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Antipsychotic Agents: Cabergoline may diminish the therapeutic effect of Antipsychotic Agents. Risk X: Avoid combination

Bromocriptine: Ergot Derivatives may enhance the adverse/toxic effect of Bromocriptine. Risk X: Avoid combination

Clarithromycin: May increase the serum concentration of Cabergoline. Risk C: Monitor therapy

Dihydroergotamine: Ergot Derivatives may enhance the vasoconstricting effect of Dihydroergotamine. Risk X: Avoid combination

Lisuride: May enhance the adverse/toxic effect of Ergot Derivatives. Risk X: Avoid combination

Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. Risk X: Avoid combination

Methysergide: Ergot Derivatives may enhance the vasoconstricting effect of Methysergide. Risk X: Avoid combination

Metoclopramide: Cabergoline may diminish the therapeutic effect of Metoclopramide. Metoclopramide may diminish the therapeutic effect of Cabergoline. Risk X: Avoid combination

Nefazodone: Ergot Derivatives may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Pipamperone [INT]: Cabergoline may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of Cabergoline. Risk X: Avoid combination

Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Sulpiride: Cabergoline may diminish the therapeutic effect of Sulpiride. Sulpiride may diminish the therapeutic effect of Cabergoline. Risk X: Avoid combination

Reproductive Considerations

Cabergoline is approved for the treatment of hyperprolactinemic disorders. Increased prolactin concentrations due to a prolactinoma may cause galactorrhea, amenorrhea, oligomenorrhea or luteal phase insufficiency. Treatment with cabergoline may restore ovulatory cycles; fertility may return prior to regular menses (ES [Melmed 2011]; ESE [Luger 2021]). Cabergoline is also used off-label for the treatment of acromegaly; normalization of insulin-like growth factor 1 and growth hormone may also restore fertility in premenopausal patients with acromegaly.

Treatment with a dopamine agonist such as cabergoline is recommended for patients with a prolactinoma who are trying to conceive (ES [Melmed 2011]; ESE [Luger 2021]). Patients should be treated with the lowest dose possible until pregnancy is confirmed (ESE [Luger 2021]). Cabergoline may be used for patients with acromegaly who are trying to conceive; discontinue once pregnancy is confirmed (ESE [Luger 2021]).

Normalizing prolactin concentrations during dopamine agonist treatment for a micro- or macroadenoma also improves fertility by restoring nocturnal penile tumescence, sperm count and sperm motility (ES [Melmed 2011]).

Pregnancy Considerations

Cabergoline is approved for the treatment of hyperprolactinemic disorders. Data related to the use of cabergoline for the treatment of hyperprolactinemia during pregnancy are available but limited compared to the use of other agents (Almistehi 2018; Auriemma 2013; Colao 2008; Lebbe 2010; Moltich 2015; Ricci 2002; Robert 1996; Stalldecker 2010). Although available evidence suggests cabergoline use early in pregnancy does not cause harm to the fetus, it is recommended that dopamine agonist therapy be discontinued once pregnancy is discovered (ES [Melmed 2011]; ESE [Luger 2021]).

If treatment of a prolactinoma during pregnancy is required, a dopamine agonist such as cabergoline may be used. Serum prolactin concentrations are increased during pregnancy; monitoring prolactin levels may not be reliable for tumor progression (ES [Melmed 2011]; ESE [Luger 2021]).

If treatment for acromegaly (off-label use) is required during pregnancy for worsening symptoms (such as headache) or evidence of tumor growth, use of cabergoline may be considered (ES [Katznelson 2014]). Monitoring of insulin-like growth factor 1 and/or growth hormone (GH) are not recommended during pregnancy as an active placental GH variant present in maternal blood limits the usefulness of the results (ES [Katznelson 2014]; ESE [Luger 2021]).

Data related to cabergoline for the treatment of Cushing disease (off-label use) during pregnancy are limited. Medication may be considered for patients when surgery is not an option or for symptomatic control at initial diagnosis; agents other than cabergoline may be preferred (ES [Nieman 2015]; ESE [Luger 2021]; Nakhleh 2016; Sek 2017).

Cabergoline is contraindicated in patients with uncontrolled hypertension; use is not recommended by the manufacturer in patients with pregnancy-induced hypertension (eg, preeclampsia, eclampsia, postpartum hypertension) unless benefit outweighs potential risk.

Breastfeeding Considerations

It is not known if cabergoline is present in breast milk.

Cabergoline interferes with lactation. When used for the treatment of hyperprolactinemic disorders (idiopathic or caused by pituitary adenomas), cabergoline should not be given to patients postpartum who are breastfeeding or who are planning to breastfeed.

Cabergoline has been studied for maternal use immediately postpartum when the inhibition of physiologic lactation is needed for medical reasons (eg, stillbirth, death of the newborn, severe or acute maternal medical conditions) (Boucoiran 2021; Buhendwa 2008; Humphrey 2018; Nisha 2009). The Health and Human Services perinatal HIV guidelines suggest use of cabergoline may be considered for lactation inhibition in select patients with HIV infection (HHS [perinatal] 2023).

Cabergoline has also been studied for use in breastfeeding patients with an overabundant milk supply (hypergalactia) who do not respond to preferred therapies to reduce milk production. When used for this indication, breast milk should be discarded for ~5 days after using cabergoline (ABM [Johnson 2020]; Eglash 2014).

Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.

Dietary Considerations

Take with food.

Monitoring Parameters

Blood pressure (both sitting/supine and standing); serum prolactin level (monthly until normalized); erythrocyte sedimentation rate, chest x-ray, and serum creatinine (at baseline and during therapy as needed); signs and symptoms of pleuropulmonary disease, renal insufficiency, ureteral/abdominal vascular obstruction, and cardiac failure.

Echocardiogram: Monitor as clinically indicated. Although the US labeling states that an echocardiogram should be done at baseline and every 6 to 12 months during therapy, current guidelines suggest that patients receiving doses ≤2 mg/week may not require routine echocardiography to monitor for cardiac valve abnormalities (ES [Katznelson 2014]; ES [Melmed 2011]).

Acromegaly (off-label use): Insulin-like growth factor 1 (IGF-1), growth hormone, and prolactin every 4 to 6 weeks after dose adjustment then every 4 to 6 months after normalization of IGF-1 (AACE [Katznelson 2011]; Abs 1998; ACG [Melmed 2018]).

Cushing disease (off-label use): Urinary free cortisol (24-hour) every 1 to 2 months during dose titration, then periodically (Godbout 2010; Pivonello 2009).

Reference Range

Acromegaly (off-label use): Age-normalized serum insulin-like growth factor 1 (IGF-1) and a random growth hormone (GH) <1 ng/mL (SI: <1 mcg/L) correlate with disease control; consider targeting postoperative GH level <0.4 ng/mL (SI: <0.4 mcg/L) if ultra-sensitive GH assay is available; use of the same IGF-1 and GH assay in the same patient throughout management is suggested (ES [Katznelson 2014]; ACG [Melmed 2018]).

Mechanism of Action

Cabergoline is a long acting dopamine receptor agonist with a high affinity for D2 receptors; prolactin secretion by the anterior pituitary is predominantly under hypothalamic inhibitory control exerted through the release of dopamine. It is a potent 5-HT2B-receptor agonist, which may contribute to observed fibrotic/valvulopathic events.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Extensive, particularly to the pituitary

Protein binding: 40% to 42%

Metabolism: Extensively hepatic via hydrolysis; minimal CYP mediated metabolism

Half-life elimination: 63 to 69 hours

Time to peak, plasma: 2 to 3 hours

Excretion: Primarily feces (~60%); urine (~22%, <4% as unchanged drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Patients with severe insufficiency (Child-Pugh score >10) show a substantial increase in the mean cabergoline Cmax and AUC.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Caberlex | Dostinex | Evadad;
  • (AR) Argentina: Cabaser | Caberpar | Cabertemis | Cabertrix | Dostinex | Lac stop | Lactamax | Triaspar;
  • (AT) Austria: Cabaseril | Dostinex;
  • (AU) Australia: Apo cabergoline | Bergoline | Cabaser | Cobasol | Dostan | Dostinex | Tinexa;
  • (BD) Bangladesh: Argolin | Caber | Cabergol | Caberol | Cabolac | Cabolin;
  • (BE) Belgium: Cabergoline teva | Dostinex | Sostilar;
  • (BG) Bulgaria: Cabaser | Dostinex;
  • (BR) Brazil: Bergox | Caberedux | Cabergolina | Cabergolina germed pharma | Cabertrix | Dostinex;
  • (CH) Switzerland: Cabaser | Dostinex;
  • (CL) Chile: Cabertrix | Dostinex;
  • (CO) Colombia: Alactin | Cabergolina | Cabertrix | Dostinex | Ergolin | Prolastat;
  • (CZ) Czech Republic: Cabera | Dostinex;
  • (DE) Germany: Cabaser | Cabaseril | Cabergolin 1A Pharma | Cabergolin AL | Cabergolin Beta | Cabergolin CT | Cabergolin Sandoz | Cabergolin stada | Cabergolin Teva | Cabergoline teva | Dostinex;
  • (DO) Dominican Republic: Cabertrix | Dostinex;
  • (EC) Ecuador: Cabergolina | Caberkana | Cabertrix | Dostinex | Lactinese | Prolactinox | Prolastat;
  • (EE) Estonia: Dostinex;
  • (EG) Egypt: Cabergamoun | Cabrostinex | Delcabrin | Dostinex | Elonda | Golinosab | Golinotech | Hypolact | Jakaranda | Marvigoline | Nostifix | Remigoline;
  • (ES) Spain: Cabergolina Teva | Dostinex | Sogilen;
  • (ET) Ethiopia: Dostinex;
  • (FI) Finland: Cabaser | Dostinex;
  • (FR) France: Cabergoline sandoz | Cabergoline teva | Dostinex;
  • (GB) United Kingdom: Cabaser | Dostinex;
  • (GR) Greece: Dostinex;
  • (HK) Hong Kong: Dostinex;
  • (HR) Croatia: Dostinex;
  • (HU) Hungary: Cabergoline teva;
  • (IE) Ireland: Cabaser | Dostinex;
  • (IL) Israel: Cabaser | Cabotrim | Dostinex;
  • (IN) India: Cabanine | Cabercet | Caberlact | Caberlin | Cabernorm | Cabgolin | Cabgon | Cabliz | Cablyn | Cabre | Cabtas | Calyn | Camforte | Cb Lin | Colette | Lactocab | Parcar | Zuricab;
  • (IT) Italy: Actualene | Cabaser | Cabergolina Rat | Dostinex;
  • (JO) Jordan: Bergo | Dostinex | Lovista | Prolin;
  • (JP) Japan: Cabaser | Cabergoline Amel | Cabergoline Towa;
  • (KE) Kenya: Caberlin | Dostinex | Nostifix;
  • (KR) Korea, Republic of: Caverlactin | Dostinen | Dostinex;
  • (KW) Kuwait: Dostinex;
  • (LB) Lebanon: Dostinex | Proctin;
  • (LT) Lithuania: Cabaseril | Cabergolin AL | Cabergolin CT | Cabergolin rph | Cabergolin Sandoz | Cabergolin stada | Cabergolin Teva | Dostinex | Sogilen;
  • (LU) Luxembourg: Dostinex | Sostilar;
  • (LV) Latvia: Cabergolin stada | Dostinex;
  • (MA) Morocco: Dostinex;
  • (MX) Mexico: Anuar | Anuar asf | Cabergolina | Caprolution | Dailet | Dostinex | Empercroz | Evemgleafem | Lacrastop | Logrecar | Omepisa | Perprolim | Progofhal | Sheldy | Trasgo | Vinreda;
  • (MY) Malaysia: Dostinex;
  • (NG) Nigeria: Dostinex | Synergo;
  • (NL) Netherlands: Cabergoline fisher | Cabergoline medcor | Cabergoline PCH | Cabergoline sandoz | Dostinex;
  • (NO) Norway: Cabaser | Dostinex;
  • (NZ) New Zealand: Dostinex;
  • (PE) Peru: Cabergol | Cabergolina | Cabernex | Dostinex | Lactinese | Promelac;
  • (PL) Poland: Cabergoline teva | Dostinex;
  • (PR) Puerto Rico: Dostinex;
  • (PT) Portugal: Dostinex;
  • (PY) Paraguay: Cabertrix;
  • (QA) Qatar: Bergo | Dostinex | Lovista;
  • (RO) Romania: Dostinex;
  • (RU) Russian Federation: Agalates | Bergolak | Dostinex;
  • (SA) Saudi Arabia: Dostinex | Lovista | Nostifix;
  • (SE) Sweden: Cabaser | Cabergoline hexal | Cabergoline ratiopharm | Cabergoline sandoz | Dostinex | Kabergolin Ebb | Kabergolin ivax;
  • (SG) Singapore: Dostinex;
  • (SI) Slovenia: Cabergolina | Dostinex;
  • (SK) Slovakia: Cabest | Dostinex;
  • (TN) Tunisia: Cabergol | Caberlex | Dostinex | Prolact;
  • (TR) Turkey: Cabaser | Dostinex;
  • (TW) Taiwan: Dostinex;
  • (UA) Ukraine: Alactin | Caberlin;
  • (UY) Uruguay: Cabaser | Caberpar | Cabertrix | Dostinex | Neurodop;
  • (VE) Venezuela, Bolivarian Republic of: Alactin | Cabergolina | Caberguni | Dostinex | Prolastat;
  • (ZA) South Africa: Arigoline | Dostinex
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.
  2. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374-378. doi:10.1210/jcem.83.2.4556 [PubMed 9467544]
  3. Almistehi WM, Almalki MH. Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline. Endocrinol Diabetes Metab Case Rep. 2018;2018. pii: 18-0099. doi:10.1530/EDM-18-0099 [PubMed 30159146]
  4. Auriemma RS, Perone Y, Di Sarno A, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013;98(1):372-379. doi:10.1210/jc.2012-3039 [PubMed 23162092]
  5. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039-1062. [PubMed 22851801]
  6. Belmonte Y, de Fàbregues O, Marti M, Domingo C. Pleuropulmonary toxicity of another anti-Parkinson's drug: cabergoline. Open Respir Med J. 2009;3:90-93. doi:10.2174/1874306400903010090 [PubMed 19572029]
  7. Boucoiran I, Roy M, Poliquin V, et al. Evaluation of cabergoline for lactation inhibition in women living with HIV. Int J STD AIDS. 2021;32(7):654-661. doi:10.1177/0956462420984694 [PubMed 33612017]
  8. Bronstein MD. Prolactinomas and Pregnancy. Pituitary. 2005;8(1):31-38. [PubMed 16411066]
  9. Budayr A, Tan TC, Lo JC, et al. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocr Disord. 2020;20(1):25. doi:10.1186/s12902-020-0507-8 [PubMed 32075620]
  10. Buhendwa L, Zachariah R, Teck R, et al. Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi. Trop Doct. 2008;38(1):30-32. doi:10.1258/td.2007.060091 [PubMed 18302861]
  11. Bulwer C, Conn R, Shankar A, et al. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clin Endocrinol (Oxf). 2017;86(6):862-864. doi:10.1111/cen.13339 [PubMed 28346715]
  12. Cabergoline tablets, USP [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; April 2022.
  13. Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern Med J. 2009;39(4):266-267. doi:10.1111/j.1445-5994.2009.01920.x [PubMed 19402868]
  14. Colao A, Abs R, Bárcena DG. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008;68(1):66-71. doi:10.1111/j.1365-2265.2007.03000.x [PubMed 17760883]
  15. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85(6):2247-2252. doi:10.1210/jcem.85.6.6657 [PubMed 10852458]
  16. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61(2):209-215. doi:10.1111/j.1365-2265.2004.02082.x [PubMed 15272916]
  17. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86(11):5256-5261. doi:10.1210/jcem.86.11.8054 [PubMed 11701688]
  18. Dostinex (cabergoline) [prescribing information]. New York, NY: Pfizer; August 2014.
  19. Dostinex (cabergoline) [prescribing information]. New York, NY: Pfizer; December 2019.
  20. Dostinex (cabergoline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2015.
  21. Eglash A. Treatment of maternal hypergalactia. Breastfeed Med. 2014;9(9):423-425. doi:10.1089/bfm.2014.0133 [PubMed 25361472]
  22. European Multicentre Study Group for Cabergoline in Lactation Inhibition. Single Dose Cabergoline Versus Bromocriptine in Inhibition of Puerperal Lactation: Randomised, Double-Blind, Multicentre Study. BMJ. 1991;302(6789):1367-1371.
  23. Falhammar H, Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009;190(2):97. doi:10.5694/j.1326-5377.2009.tb02289.x [PubMed 19236300]
  24. Ferrari C, Paracchi A, Mattei AM, et al. Cabergoline in the Long-Term Therapy of Hyperprolactinemic Disorders. Acta Endocrinol (Copenh). 1992;126(6):489-494. [PubMed 1642081]
  25. Frank W, Moritz R, Becke B, Pauli R. Low dose cabergoline induced interstitial pneumonitis. Eur Respir J. 1999;14(4):968-970. doi:10.1034/j.1399-3003.1999.14d40.x [PubMed 10573251]
  26. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385-1396. [PubMed 22937989]
  27. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163(5):709-716. doi:10.1530/EJE-10-0382 [PubMed 20702648]
  28. Giusti M, Porcella E, Carraro A, et al. A Cross-Over Study With the Two Novel Dopaminergic Drugs Cabergoline and Quinagolide in Hyperprolactinemic Patients. J Endocrinol Invest. 1994;17(1):51-57. [PubMed 7911813]
  29. Gupta P, Tundup T, Singh J, Deb KS, Verma R, Kumar N. Treatment complexities in psychosis associated with cabergoline treatment in patients having pituitary prolactinomas. Asian J Psychiatr. 2018;31:129-132. doi:10.1016/j.ajp.2018.01.011 [PubMed 29482124]
  30. Gürbüz F, Yağcı-Küpeli B, Kör Y, et al. The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma. J Pediatr Endocrinol Metab. 2014;27(1-2):159-163. doi:10.1515/jpem-2013-0151 [PubMed 23945126]
  31. Harris K, Murphy KE, Horn D, MacGilivray J, Yudin MH. Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review [published online ahead of print, July 6, 2019]. J Obstet Gynaecol Can. 2019;S1701-2163(19)30304-4. doi:10.1016/j.jogc.2019.03.014 [PubMed 31285168]
  32. Humphrey S, Baechler M, Schiff M et al. Cabergoline for lactation suppression among HIV+ and HIV- women. Top Antivir Med. 2018;26(suppl 1):362s.
  33. Johnson HM, Eglash A, Mitchell KB, et al; Academy of Breastfeeding Medicine. ABM clinical protocol #32: management of hyperlactation. Breastfeed Med. 2020;15(3):129-134. doi:10.1089/bfm.2019.29141.hmj [PubMed 32031417]
  34. Kasuki L, Dalmolin MD, Wildemberg LE, Gadelha MR. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clin Endocrinol (Oxf). 2018;88(6):889-895. doi:10.1111/cen.13595 [PubMed 29520805]
  35. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract. 2011;17(suppl 4):1-44. [PubMed 21846616]
  36. Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. doi:10.1210/jc.2014-2700 [PubMed 25356808]
  37. Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf). 2010;73(2):236-242. doi:10.1111/j.1365-2265.2010.03808.x [PubMed 20455894]
  38. Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462 [PubMed 34425558]
  39. Mehta NK, Malkani S, Ockene I. Spontaneous coronary artery dissection during cabergoline therapy. Tex Heart Inst J. 2012;39(1):92-94. [PubMed 22412238]
  40. Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561. doi:10.1038/s41574-018-0058-5 [PubMed 30050156]
  41. Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi:10.1210/jc.2010-1692 [PubMed 21296991]
  42. Miwa H, Kondo T. Hair loss induced by dopamine agonist: case report and review of the literature. Parkinsonism Relat Disord. 2003;10(1):51-52. doi:10.1016/s1353-8020(03)00058-0 [PubMed 14499208]
  43. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-13. doi:10.1530/EJE-14-0848 [PubMed 25805896]
  44. Moyes VJ, Metcalfe KA, Drake WM. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol. 2008;159(5):541-545. doi:10.1530/EJE-08-0306 [PubMed 18708434]
  45. Nakhleh A, Saiegh L, Reut M. Cabergoline treatment for recurrent Cushing's disease during pregnancy. Hormones (Athens). 2016;15(3):453-458. doi:10.14310/horm.2002.1685 [PubMed 27394707]
  46. Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818 [PubMed 26222757]
  47. Nisha S, Uma S, Vineeta S. Role of newer drug cabergolin in lactation suppression as compared to estrogen-androgen combination. J Obstet Gynecol India. 2009;59(2):152-155.
  48. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology. 2006;67(6):1040-1046. [PubMed 16931508]
  49. Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721-4727. doi:10.1210/jc.2007-2758 [PubMed 18812485]
  50. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223-230. doi:10.1210/jc.2008-1533 [PubMed 18957500]
  51. Rains CP, Bryson HM, and Fitton A. Cabergoline: A Review of Its Pharmacological Properties and Therapeutic Potential in the Treatment of Hyperprolactinemia and Inhibition of Lactation. Drugs. 1995;49(2):255-279. [PubMed 7729332]
  52. Refer to manufacturer's labeling.
  53. Ricci E, Parazzini F, Motta T, et al. Pregnancy Outcome After Cabergoline Treatment in Early Weeks of Gestation. Reprod Toxicol. 2002;16(6):791-793. [PubMed 12401507]
  54. Robert E, Musatti L, Piscitelli G, et al. Pregnancy Outcome After Treatment With the Ergot Derivative, Cabergoline. Reprod Toxicol. 1996;10(4):333-337. [PubMed 8829257]
  55. Roth BL. Drugs and Valvular Heart Disease. N Engl J Med. 2007;356(1):6-9. [PubMed 17202450]
  56. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38. [PubMed 17202453]
  57. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011;(3):CD006009. [PubMed 21412893]
  58. Sek KS, Deepak DS, Lee KO. Use of cabergoline for the management of persistent Cushing's disease in pregnancy. BMJ Case Rep. 2017;2017. pii: bcr-2016-217855. doi:10.1136/bcr-2016-217855 [PubMed 28710189]
  59. Stalldecker G, Mallea-Gil MS, Guitelman M, et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary. 2010;13(4):345-350. doi:10.1007/s11102-010-0243-6 [PubMed 20676778]
  60. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 2004;63(12):2272-2279. [PubMed 15623686]
  61. Stiles CE, Lloyd G, Bhattacharyya S, et al. Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab. 2021;106(2):e711-e720. doi:10.1210/clinem/dgaa882 [PubMed 33247916]
  62. Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. Heart. 2004;90(8):e47. doi:10.1136/hrt.2004.036236 [PubMed 15253989]
  63. Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord. 2007;22(5):696-703. [PubMed 17274039]
  64. Tulloch KJ, Dodin P, Tremblay-Racine F, Elwood C, Money D, Boucoiran I. Cabergoline: a review of its use in the inhibition of lactation for women living with HIV. J Int AIDS Soc. 2019;22(6):e25322. doi:10.1002/jia2.25322 [PubMed 31183987]
  65. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed October 5, 2016.
  66. US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf. Updated January 31, 2023. Accessed February 23, 2023.
  67. Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary. 2011;14(2):148-156. doi:10.1007/s11102-010-0272-1 [PubMed 21104199]
  68. Webster J, Piscitelli G, Polli A, et al. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. N Engl J Med. 1994;331(14):904-909. [PubMed 7915824]
  69. Webster J, Piscitelli G, Polli A, et al. Dose-Dependent Suppression of Serum Prolactin by Cabergoline in Hyperprolactinaemia: A Placebo Controlled, Double Blind, Multicentre Study. Clin Endocrinol (Oxf). 1992;37(6):534-541. [PubMed 1286524]
  70. Webster J, Piscitelli G, Polli A, et al. The Efficacy and Tolerability of Long-Term Cabergoline Therapy in Hyperprolactinaemic Disorders: An Open, Uncontrolled, Multicentre Study. Clin Endocrinol (Oxf). 1993;39(3):323-329. [PubMed 7900937]
  71. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388 [PubMed 27856776]
  72. Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. doi:10.1007/s12020-017-1444-9 [PubMed 29043560]
  73. Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease. N Engl J Med. 2007;356(1):39-46. [PubMed 17202454]
Topic 8600 Version 279.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟